Genmab A/S (GNMSF) Stock Price, News & Analysis

Company Overview

Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.

Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies. Its research and development activities have contributed to medicines including DARZALEX (daratumumab) for multiple myeloma, RYBREVANT (amivantamab) for certain lung cancers, and EPKINLY (epcoritamab) for certain B-cell lymphomas. Genmab has developed these and other products through collaborations with global pharmaceutical companies, including Johnson & Johnson and AbbVie.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab serves international markets through research, development, partnerships and commercialization activities in Europe, North America and other regions. The company is led by President and Chief Executive Officer Jan van de Winkel, who has been associated with Genmab’s leadership since the company’s early development.

Key Stats

• Today's Range: $355.00 to $355.00
• 50-Day Range: $282.00 to $355.00
• 52-Week Range: $232.34 to $355.00
• Volume: N/A
• Average Volume: 109 shs
• Market Capitalization: $21.86 billion
• P/E Ratio: 27.84
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genmab A/S.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 27.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 27.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.77.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.32% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 47.36, which indicates bearish sentiment.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 3.38%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.27

News Sentiment

Genmab A/S has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

Genmab A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/17/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:GNMSF
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: 45-7020-2729
• Employees: 3,029
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): $12.75
• Trailing P/E Ratio: 27.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $963 million
• Net Margins: 19.08%
• Pretax Margin: 21.93%
• Return on Equity: 14.89%
• Return on Assets: 7.73%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 2.46
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $3.72 billion
• Price / Sales: 5.88
• Cash Flow: $15.65 per share
• Price / Cash Flow: 22.68
• Book Value: $88.49 per share
• Price / Book: 4.01

Miscellaneous

• Outstanding Shares: 61,570,000
• Free Float: 60,622,000
• Market Cap: $21.86 billion
• Optionable: Not Optionable
• Beta: 0.75